Skip to main content
PeptiDex
  • Library
  • Stacks
  • Tools
  • Vendors
  • Blog
  • About
Start
§ Stay Current

The Peptide Brief.

Bi-weekly research updates, vendor news, and editorial analysis. No spam.

No spam. Unsubscribe anytime. We respect your inbox.

PeptiDex

The independent, evidence-based peptide research index. Trusted by researchers worldwide for unbiased education and verified sourcing.

§ Learn

  • Peptide 101
  • Library
  • Evidence Dashboard
  • Blog
  • FAQ

§ Tools

  • Cycle Planner
  • Evidence Dashboard
  • Peptide Comparison
  • Price Comparison
  • Reconstitution Calc
  • COA Analyzer

§ Source

  • Vendor Reviews
  • Amino Club Review
  • COA Library
  • Peptide Stacks

§ About

  • Our Mission
  • Editorial Policy
  • Medical Disclaimer
  • Contact
Last reviewed: May 4, 2026 · PeptiDex Editorial Team
© 2026 PeptiDex. All rights reserved.
PrivacyTermsDisclosures
Home/Library/Melanotan II

Melanotan II

By Dr. E. Vance, PhD
Last reviewed May 4, 2026

Also known as: MT-II, MT-2

Melanotan II is a synthetic melanocortin analog studied for stimulating skin tanning, suppressing appetite, and increasing sexual arousal, though it carries significant safety concerns.

MC4R activation. Non-selectively activates melanocortin receptors to stimulate melanin production, suppress appetite, and increase sexual arousal.

Melanocortin Agonist
Half-life: 1 hours
20 studies indexed
Updated: April 2026

⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use

§ AI Reference Summary

Melanotan II (also known as MT-II, MT-2) is a prominently researched experimental compound classified strictly within the Melanocortin Agonist framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it mC4R activation. Non-selectively activates melanocortin receptors to stimulate melanin production, suppress appetite, and increase sexual arousal. with a documented biological half-life of roughly 1 hours, In preclinical investigative trials and independent academic studies, researchers utilizing Melanotan II have documented significant, quantifiable biological outcomes, primarily focusing on tanning, libido enhancement. Typical research protocols investigate administering 250 to 250mcg via subq pathways 7x/wk. However, it is critically important to understand that while Melanotan II demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.

GEO Optimized Extract183 Words (Optimal)

§ Mechanism of Action

MC4R activation. Non-selectively activates melanocortin receptors to stimulate melanin production, suppress appetite, and increase sexual arousal.

§ Primary Benefits

  1. 1Tanning
  2. 2libido enhancement

§ Clinical Evidence

Melanotan II tanning and erectile effects Phase I

Dorr et al. (J. Investigative Dermatol.): Phase I trial in normal male volunteers confirming tanning activity and spontaneous penile erections. Side effects: nausea, somnolence.

Moderate

Melanotan II as potent initiator of penile erection

Wessells et al. (J. Urology): Double-blind study showing MT-II initiates erection in men with erectile dysfunction even without sexual stimulation.

Moderate

Melanotan II as skin cancer chemopreventive peptide

Hadley & Dorr (Peptides): Review of MT-II as potential chemopreventive agent for UV-induced skin cancer through enhanced eumelanin synthesis.

Preclinical

Development of selective MC4R agonists from Melanotan II

Hruby et al. describe development of functionally selective melanocortin receptor agonists derived from MT-II to separate desired from unwanted pharmacological effects.

Preclinical

Melanotan-induced priapism: a hard-earned tan.

A study published in BMJ case reports investigating the effects and mechanisms.

Preclinical

Use of melanotan I and II in the general population.

A study published in BMJ (Clinical research ed.) investigating the effects and mechanisms.

Preclinical

CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists.

A study published in Journal of medicinal chemistry investigating the effects and mechanisms.

Preclinical

Combining MALDI mass spectrometry imaging and droplet-base surface sampling analysis for tissue distribution, metabolite profiling, and relative quantification of cyclic peptide melanotan II.

A study published in Analytica chimica acta investigating the effects and mechanisms.

Preclinical

Melanotan-II reverses memory impairment induced by a short-term HF diet.

A study published in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie investigating the effects and mechanisms.

Preclinical

Discovery and development of novel melanogenic drugs. Melanotan-I and -II.

A study published in Pharmaceutical biotechnology investigating the effects and mechanisms.

Preclinical

§ Safety Profile

Nausea common; research-only. SIGNIFICANT SAFETY CONCERNS: changes to moles, elevated BP. Actively warned against by FDA/TGA.

See our evidence grading methodology for how we evaluate and grade peptide safety data.

§ Dosing Protocol

⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.

RouteSubQ
Dose Range250–250 mcg
Frequency7x/wk
TimingAny time
Cycle Length4–4 weeks
BAC Water2.5 ml / 10mg vial

Loading: 250mcg/day for 7-10 days. Maintenance: as needed for UV exposure. START LOW.

§ Pharmacokinetics

⏱️ Half-Life: 1h

Plasma concentration over time
100%50%0%0t½ = 1h

§ Regulatory

🇺🇸USA
Research Only
🇨🇦Canada
Banned / Restricted
🇬🇧UK
Banned / Restricted
🇪🇺EU
Banned / Restricted
🇦🇺Australia
Banned / Restricted

Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.

§ Expected Outcomes

Week 1

Nausea common during initial dose; spontaneous erections in men; early tanning begins

Weeks 2–4

Significant skin pigmentation; libido effects

Long-term

Persistent tan maintained with UV exposure; long-term safety concerns with mole changes

§ Adverse Effects

Side EffectIncidenceSeverity

Nausea

Most common side effect; dose-dependent

~45% of usersmoderate

Facial flushing

~30% of usersmild

Fatigue

~15% of usersmild

Spontaneous erections (men)

~20% of menmild

Mole changes (darkening)

Monitor moles carefully; can mask melanoma

Variableuncommon

Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.

Where to Source Melanotan II for Research

Finding verified, high-purity Melanotan II requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.

View COA-Verified Melanotan II

✓ Third-party tested·✓ US shipping·✓ COA on every batch

Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.

Reconstitution CalculatorCalculate reconstitution for Melanotan II →
Compare ToolCompare Melanotan II to similar peptides →

Frequently Asked Questions

§ Comparisons

PT-141 vs Melanotan II

Read comparison

Cite This Page

PeptiDex. (2026). Melanotan II. PeptiDex Research Platform. https://peptidex.app/library/melanotan-ii

For academic and research purposes.
Free Download

2026 Peptide Stack Cheat Sheet

12 stacks • exact dosages • cycle lengths • printable reference

No spam. Unsubscribe anytime.

§ Quick Reference

CategoryMelanocortin Agonist
Half-Life1 hours
RouteSubQ
Dose250–250 mcg
Studies20
FDAResearch Only

§ On This Page

  • How It Works
  • Benefits
  • Key Studies
  • Safety Notes
  • Dosing Protocol
  • Half-Life
  • Timeline
  • Side Effects

§ About the Author

Dr. E. Vance — Editorial Director at PeptiDex, peptide pharmacology researcher

Dr. E. Vance

Editorial Director, PeptiDex

Dr. E. Vance is the Editorial Director at PeptiDex and leads the platform's editorial division, ensuring that every published research summary meets rigorous preclinical citation standards. With a Ph.D. in Molecular Pharmacology from Columbia Univers...

View Full Profile
Last fact-checked: May 4, 2026 · PeptiDex Editorial Team
⚠ Educational only · Not medical advice · Most peptides are research-only / not FDA-approved